Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

10/759,345

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:10:28 ON 01 AUG 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items

```
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:54:20 ON 01 AUG 2005

=> e cidofovir/cn
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
The EXPAND command is used to look at the index in a file
which has an index.  This file does not have an index.

=> fie reg
FIE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> e cidofovir/cn
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
The EXPAND command is used to look at the index in a file
which has an index.  This file does not have an index.

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.42       0.42

FILE 'REGISTRY' ENTERED AT 12:55:10 ON 01 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JUL 2005  HIGHEST RN 857722-60-2
DICTIONARY FILE UPDATES:  29 JUL 2005  HIGHEST RN 857722-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from     *
* the IDE default display format and the ED field has been added,       *
* effective March 20, 2005.  A new display format, IDERL, is now        *
```

```
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> e cidofovir/cn
E1            1     CIDIROL/CN
E2            1     CIDOCETINE/CN
E3            1 --> CIDOFOVIR/CN
E4            1     CIDOFOVIR DIPHOSPHATE/CN
E5            1     CIDOFOVIR HYDRATE/CN
E6            1     CIDOMYCIN/CN
E7            1     CIDOPHYLLINE/CN
E8            1     CIDOTEN/CN
E9            1     CIDOVIR/CN
E10           1     CIDOXEPIN/CN
E11           1     CIDOXEPIN HYDROCHLORIDE/CN
E12           1     CIDR/CN

=> s e3
L1            1 CIDOFOVIR/CN

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.03       5.45

FILE 'CAPLUS' ENTERED AT 12:55:31 ON 01 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 1 Aug 2005  VOL 143 ISS 6
FILE LAST UPDATED: 31 Jul 2005  (20050731/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l1
L2          563 L1
```

```
=> s l2 and alcohol
         225925 ALCOHOL
         155811 ALCOHOLS
         353092 ALCOHOL
                  (ALCOHOL OR ALCOHOLS)
         556434 ALC
         184857 ALCS
         650819 ALC
                  (ALC OR ALCS)
         777558 ALCOHOL
                  (ALCOHOL OR ALC)
L3           35 L2 AND ALCOHOL

=> s l2 and (alkylglycerol or alkylpropanediol or alkylthioglycerol or
alkoxyalkanol or alkylethanediol)
            193 ALKYLGLYCEROL
            160 ALKYLGLYCEROLS
            290 ALKYLGLYCEROL
                  (ALKYLGLYCEROL OR ALKYLGLYCEROLS)
             21 ALKYLPROPANEDIOL
             12 ALKYLPROPANEDIOLS
             31 ALKYLPROPANEDIOL
                  (ALKYLPROPANEDIOL OR ALKYLPROPANEDIOLS)
              2 ALKYLTHIOGLYCEROL
             93 ALKOXYALKANOL
             77 ALKOXYALKANOLS
            139 ALKOXYALKANOL
                  (ALKOXYALKANOL OR ALKOXYALKANOLS)
              3 ALKYLETHANEDIOL
              3 ALKYLETHANEDIOLS
              5 ALKYLETHANEDIOL
                  (ALKYLETHANEDIOL OR ALKYLETHANEDIOLS)
L4            6 L2 AND (ALKYLGLYCEROL OR ALKYLPROPANEDIOL OR ALKYLTHIOGLYCEROL
                OR ALKOXYALKANOL OR ALKYLETHANEDIOL)

=> d l4 ibib hitstr abs 1-6

L4   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2005:129464  CAPLUS
DOCUMENT NUMBER:          142:366750
TITLE:                    Comparison of the antiviral activities of alkoxyalkyl
                          and alkyl esters of cidofovir against human and murine
                          cytomegalovirus replication in vitro
AUTHOR(S):                Wan, William B.; Beadle, James R.; Hartline, Caroll;
                          Kern, Earl R.; Ciesla, Stephanie L.; Valiaeva,
                          Nadejda; Hostetler, Karl Y.
CORPORATE SOURCE:         Veterans Administration San Diego Healthcare System
                          and the Department of Medicine, University of
                          California, San Diego, La Jolla, CA, 92093-0676, USA
SOURCE:                   Antimicrobial Agents and Chemotherapy (2005), 49(2),
                          656-662
                          CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER:                American Society for Microbiology
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
IT   113852-37-2, Cidofovir
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (comparison of antiviral activities of alkoxyalkyl and alkyl esters of
```

cidofovir against human and murine cytomegalovirus replication in vitro)
RN 113852-37-2 CAPLUS
CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Alkoxyalkyl esters of cidofovir (CDV) have substantially greater antiviral activity and selectivity than unmodified CDV against herpesviruses and orthopoxviruses in vitro. Enhancement of antiviral activity was also noted when cyclic CDV was esterified with **alkoxyalkanols.** In vitro antiviral activity of the most active analogs against human cytomegalovirus (HCMV) and orthopoxviruses was increased relative to CDV up to 1000- or 200-fold, resp. Alkyl chain length and linker structure are important potential modifiers of antiviral activity and selectivity. In this study, the authors synthesized a series of alkoxyalkyl esters of CDV or cyclic CDV with alkyl chains from 8 to 24 atoms and having linker moieties of glycerol, propanediol, and ethanediol. The authors also synthesized alkyl esters of CDV which lack the linker to determine if the alkoxyalkyl linker moiety is required for activity. The new compds. were evaluated in vitro against HCMV and murine CMV (MCMV). CDV or cyclic CDV analogs both with and without linker moieties were highly active against HCMV and MCMV, and their activities were strongly dependent on chain length. The most active compds. had 20 atoms esterified to the phosphonate of CDV. Both alkoxypropyl and alkyl esters of CDV provided enhanced antiviral activities against CMV in vitro. Thus, the oxypropyl linker moiety is not required for enhanced activity. CDV analogs having alkyl ethers linked to glycerol or ethanediol linker groups also demonstrated increased activity against CMV.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:538061 CAPLUS
DOCUMENT NUMBER: 141:184637
TITLE: Antiviral prophylaxis of smallpox
AUTHOR(S): Bray, Mike; Roy, Chad J.
CORPORATE SOURCE: Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
SOURCE: Journal of Antimicrobial Chemotherapy (2004), 54(1), 1-5
CODEN: JACHDX; ISSN: 0305-7453
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **113852-37-2**, Cidofovir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiviral prophylaxis of smallpox)
RN 113852-37-2 CAPLUS

CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A review. Proof-of-concept studies suggest that current defences against smallpox could be strengthened by supplementing vaccination with antiviral drug prophylaxis, based on aerosolized or orally available forms of the long-acting medication cidofovir. Delivery of aerosolized cidofovir to mice results in its prolonged retention in respiratory tissues and protection against lethal intranasal or aerosol poxviral challenge. Although cidofovir itself is not orally available, the addition of an **alkoxyalkanol** ether side-chain allows it to be absorbed from the gastrointestinal tract. This also markedly increases its antiviral activity and lengthens its intracellular half-life from roughly 3 to 8-10 days. Oral treatment also protected mice against lethal poxviral challenge. These results suggest that a single aerosol dose of cidofovir (or an **alkoxyalkanol**-ether derivative) could provide prolonged protection against initiation of smallpox infection, whereas oral treatment could prevent both initiation of infection and internal dissemination of virus. Both approaches may avoid the nephrotoxicity that occasionally results from i.v. cidofovir therapy.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:126286 CAPLUS
DOCUMENT NUMBER: 140:385553
TITLE: Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model
AUTHOR(S): Buller, R. Mark; Owens, Gelita; Schriewer, Jill; Melman, Lora; Beadle, James R.; Hostetler, Karl Y.
CORPORATE SOURCE: Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, St. Louis, MO, 63104, USA
SOURCE: Virology (2004), 318(2), 474-481
CODEN: VIRLAX; ISSN: 0042-6822
PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **113852-37-2**, Cidofovir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of ether lipid analogs of cidofovir in lethal mousepox model)
RN 113852-37-2 CAPLUS
CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Cidofovir (CDV) is a highly effective inhibitor of orthopoxvirus replication and may be used i.v. to treat smallpox or complications arising from the smallpox vaccine under an investigational new drug application (IND). However, CDV is absorbed poorly following oral administration and is inactive orally. To improve the bioavailability of CDV, others synthesized **alkoxyalkanol** esters of CDV and observed >100-fold more activity than unmodified CDV against cowpox, vaccinia, and variola virus (VARV) replication. These ether lipid analogs of CDV have high oral bioavailability in mice. In this study, we compared the oral activity of CDV with the hexadecyloxypropyl (HDP)-, octadecyloxyethyl-, oleyloxypropyl-, and oleyloxyethyl-esters of CDV in a lethal, aerosol ectromelia virus (ECTV) challenge model in A/NCR mice. Octadecyloxyethyl-CDV appeared to be the most potent CDV analog as a dose regimen of 5 mg/kg started 4 h following challenge completely blocked virus replication in spleen and liver, and protected 100% of A/NCR mice, although oral, unmodified CDV was inactive. These results suggest that this family of compds. deserves further evaluation as poxvirus.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:625949 CAPLUS

DOCUMENT NUMBER: 140:192122

TITLE: Esterification of cidofovir with **alkoxyalkanols** increases oral bioavailability and diminishes drug accumulation in kidney

AUTHOR(S): Ciesla, Stephanie L.; Trahan, Julissa; Wan, W. Brad; Beadle, James R.; Aldern, Kathy A.; Painter, George R.; Hostetler, Karl Y.

CORPORATE SOURCE: San Diego VA Healthcare System, Department of Medicine, University of California, La Jolla, CA, 92093-0676, USA

SOURCE: Antiviral Research (2003), 59(3), 163-171
CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **113852-37-2**, Cidofovir
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(esterification of cidofovir with **alkoxyalkanols** increases oral bioavailability and diminishes drug accumulation in kidney)

RN 113852-37-2 CAPLUS

CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Smallpox was eradicated by vaccination in the 1970s. However, concerns have arisen about the potential use of variola virus as a biol. weapon. Most of the world's population has little residual immunity because systematic vaccination against smallpox ceased in the early 1970s. Vaccination of key elements of the population against smallpox is again being considered. However, there are now large nos. of persons who cannot be safely vaccinated with the current vaccine because of AIDS, immunosuppressive drugs, and certain common skin disorders. It would be useful to have a potent orally active drug as an alternative for these persons in case of an outbreak of smallpox.Alkoxyalkyl esters of cidofovir (CDV) have been shown to be highly active and selective against poxviruses in vitro with activities several logs greater than the activity of unmodified CDV. This is due in large part to increased cellular penetration and conversion to CDV-diphosphate, the active antiviral. In this paper, the oral pharmacokinetics of 14C-labeled hexadecyloxypropyl-cidofir (HDP-CDV), octadecyloxyethyl-cidofir (ODP-CDV), and oleyloxypropyl-cidofir (OLP-CDV) are examined and oral bioavailability and tissue distribution assessed and compared with parenteral CDV. The alkoxyalkyl CDVs are highly orally bioavailable and do not concentrate in kidney, the site of the dose-limiting toxicity of CDV. Plasma and tissue drug levels are many times greater than the in vitro EC50s for variola, cowpox, and vaccinia viruses. Thus, the compds. are good candidates for further development for prevention and treatment of smallpox infection and the complications of vaccination.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:218837 CAPLUS
DOCUMENT NUMBER: 139:239732
TITLE: Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism
AUTHOR(S): Aldern, Kathy A.; Ciesla, Stephanie L.; Winegarden, Kristine L.; Hostetler, Karl Y.
CORPORATE SOURCE: Department of Medicine, San Diego VA Healthcare System and the University of California, La Jolla, CA, USA
SOURCE: Molecular Pharmacology (2003), 63(3), 678-681
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **113852-37-2**, Cidofovir
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(increased antiviral activity of 1-O-hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism)
RN 113852-37-2 CAPLUS
CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Recently, there has been renewed interest in finding orally active drugs against smallpox. Cidofovir (CDV) given by parenteral injection has been shown to protect against lethal poxvirus infection. We have been interested in the synthesis and evaluation of orally active derivs. of CDV. Previous studies showed that the CDV and cyclic cidofovir (cCDV) analogs 1-O-hexa-decyloxypropyl-CDV (HDP-CDV) and 1-O-hexadecyloxypropyl-cCDV (HDP-cCDV), show >100-fold increases in antiviral activity vs. the unmodified nucleosides against cells infected with orthopoxviruses, cowpox, and vaccinia virus. In contrast to CDV, HDP-CDV is orally bioavailable and has been reported to be orally active in lethal cowpox virus infection in mice. To assess the metabolic basis for the increased antiviral activity of HDP-CDV in vitro, we studied the cellular uptake and anabolic metabolism of 14C-labeled CDV, cCDV, and their **alkoxyalkanol** esters HDP-CDV and HDP-cCDV. HDP-CDV and HDP-cCDV were taken up rapidly by MRC-5 human lung fibroblasts in vitro, but uptake of CDV and cCDV was much slower. Anal. of cellular metabolites showed that levels of cidofovir diphosphate (CDV-DP), the active antiviral compound, were >100 times greater with HDP-CDV than levels observed with CDV. When cells were exposed to HDP-CDV, the intracellular half-life of CDV-DP was 10 days vs. 2.7 days reported when cells are exposed to CDV. HDP-CDV seems to circumvent poor cellular uptake by rapid association with cellular membrane phospholipids, whereas CDV uptake proceeds via the slow process of fluid endocytosis.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:240052 CAPLUS
DOCUMENT NUMBER: 137:134473
TITLE: Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir
AUTHOR(S): Kern, Earl R.; Hartline, Caroll; Harden, Emma; Keith, Kathy; Rodriguez, Natalie; Beadle, James R.; Hostetler, Karl Y.
CORPORATE SOURCE: University of Alabama School of Medicine, Birmingham, AL, USA
SOURCE: Antimicrobial Agents and Chemotherapy (2002), 46(4), 991-995
CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:134473

IT **113852-37-2**, Cidofovir
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir)

RN 113852-37-2 CAPLUS
CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The nucleotide phosphonates cidofovir (CDV) and cyclic cidofovir (cCDV) are potent antiviral compds. when administered parenterally but are not well absorbed orally. These compds. have been reported to have activity against orthopoxvirus replication in vitro and in animal models when administered parenterally or by aerosol. To obtain better oral activity, we synthesized a novel series of analogs of CDV and cCDV by esterification with two long-chain **alkoxyalkanols**, 3-hexadecyloxy-1-propanol (HDP-CDV; HDP-cCDV) or 3-octadecyloxy-1-ethanol (ODE-CDV; ODE-cCDV). Their activities were evaluated and compared with those of CDV and cCDV in human foreskin fibroblast (HFF) cells infected with vaccinia virus (VV) or cowpox virus (CV) using a plaque reduction assay. The 50% effective concns. (EC50s) against VV in HFF cells for CDV and cCDV were 46.2 and 50.6 μM compared with 0.84 and 3.8 μM for HDP-CDV and HDP-cCDV, resp. The EC50s for ODE-CDV and ODE-cCDV were 0.20 and 1.1 μM, resp. The HDP analogs were 57- and 13-fold more active than the parent nucleotides, whereas the ODE analogs were 231- and 46-fold more active than the unmodified CDV and cCDV. Similar results were obtained using CV. Cytotoxicity studies indicated that although the analogs were more toxic than the parent nucleotides, the selective index was increased by 4- to 13-fold. These results indicate that the alkoxyalkyl esters of CDV and cCDV have enhanced activity in vitro and need to be evaluated for their oral absorption and efficacy in animal models.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.48	50.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.38	-4.38

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 01 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2
DICTIONARY FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> e adefovir/cn
E1            1     ADEFLON A/CN
E2            1     ADEFLON D/CN
E3            1 --> ADEFOVIR/CN
E4            1     ADEFOVIR DIPHOSPHATE/CN
E5            1     ADEFOVIR DIPIVOXIL/CN
E6            1     ADEG/CN
E7            1     ADEHL/CN
E8            1     ADEK/CN
E9            1     ADEKA 1413/CN
E10           1     ADEKA 2014FG/CN
E11           1     ADEKA 25R1/CN
E12           1     ADEKA 25R2/CN

=> s e3
L5            1 ADEFOVIR/CN

=> e tenofovir/cn
E1            1     TENOBLOCK/CN
E2            1     TENOCYCLIDINE/CN
E3            1 --> TENOFOVIR/CN
E4            1     TENOFOVIR DF/CN
E5            1     TENOFOVIR DIPHOSPHATE/CN
E6            1     TENOFOVIR DISOPROXIL/CN
E7            1     TENOFOVIR DISOPROXIL FUMARATE/CN
E8            1     TENOFOVIR TRIPHOSPHATE/CN
E9            1     TENOLIN/CN
E10           1     TENOLOL/CN
E11           1     TENOMODULIN (HUMAN GENE TEM)/CN
E12           1     TENOMODULIN (HUMAN)/CN

=> s e3
L6            1 TENOFOVIR/CN

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    10.06      60.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -4.38

FILE 'CAPLUS' ENTERED AT 13:02:28 ON 01 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 1 Aug 2005  VOL 143 ISS 6
FILE LAST UPDATED: 31 Jul 2005  (20050731/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l5 or l6
           493 L5
           333 L6
L7         733 L5 OR L6

=> s l7 and (alkylglycerol or alkylpropanediol or alkylthioglycerol or
alkoxyalkanol or alkylethanediol)
           193 ALKYLGLYCEROL
           160 ALKYLGLYCEROLS
           290 ALKYLGLYCEROL
                 (ALKYLGLYCEROL OR ALKYLGLYCEROLS)
            21 ALKYLPROPANEDIOL
            12 ALKYLPROPANEDIOLS
            31 ALKYLPROPANEDIOL
                 (ALKYLPROPANEDIOL OR ALKYLPROPANEDIOLS)
             2 ALKYLTHIOGLYCEROL
            93 ALKOXYALKANOL
            77 ALKOXYALKANOLS
           139 ALKOXYALKANOL
                 (ALKOXYALKANOL OR ALKOXYALKANOLS)
             3 ALKYLETHANEDIOL
             3 ALKYLETHANEDIOLS
             5 ALKYLETHANEDIOL
                 (ALKYLETHANEDIOL OR ALKYLETHANEDIOLS)
L8           1 L7 AND (ALKYLGLYCEROL OR ALKYLPROPANEDIOL OR ALKYLTHIOGLYCEROL
               OR ALKOXYALKANOL OR ALKYLETHANEDIOL)

=> d l8 ibib hitstr abs

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
```

ACCESSION NUMBER: 2001:489223 CAPLUS
DOCUMENT NUMBER: 135:71256
TITLE: Phosphonoformate lipid analogs for the treatment of drug-resistant human immunodeficiency virus infection
INVENTOR(S): Hostetler, Karl Y.; Mellors, John W.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047511	A2	20010705	WO 2000-US35137	20001222
WO 2001047511	A3	20011220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395430	AA	20010705	CA 2000-2395430	20001222
BR 2000016844	A	20020910	BR 2000-16844	20001222
EP 1244459	A2	20021002	EP 2000-988322	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518495	T2	20030610	JP 2001-548106	20001222
ZA 2002005020	A	20030626	ZA 2002-5020	20020621
US 2003207843	A1	20031106	US 2002-169432	20021030
PRIORITY APPLN. INFO.:			US 1999-173610P P	19991229
			US 2000-174425P P	20000104
			WO 2000-US35137 W	20001222

OTHER SOURCE(S): MARPAT 135:71256
IT **106941-25-7**, Adefovir **147127-20-6**, Tenofovir
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(resistance to; phosphonoformate lipid analogs for treatment of drug-resistant HIV infection)
RN 106941-25-7 CAPLUS
CN Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 147127-20-6 CAPLUS
CN Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Methods are provided for treating HIV infection in a subject in need thereof which use lipid analogs of phosphonoformate-containing pharmaceutically active compds. Lipid analogs contemplated for use comprise phosphonoformates covalently linked (directly or indirectly through a linker mol.) to a substituted or unsubstituted **alkylglycerol**, **alkylpropanediol**, **alkylethanediol** , or related moiety. In particular, the invention provides methods for treating viral infections caused by viruses which have developed resistance to currently available antiviral agents, as well as methods comprising the use of invention compds. in combination with azidodeoxythymidine to minimize the selection of drug-resistant HIV variants during therapy.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.64	77.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-5.11

STN INTERNATIONAL LOGOFF AT 13:05:16 ON 01 AUG 2005

10/759,345



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

563 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
563 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e adefovir/cn
E1            1     ADEFLON A/CN
E2            1     ADEFLON D/CN
E3            1 --> ADEFOVIR/CN
E4            1     ADEFOVIR DIPHOSPHATE/CN
E5            1     ADEFOVIR DIPIVOXIL/CN
E6            1     ADEG/CN
E7            1     ADEHL/CN
E8            1     ADEK/CN
E9            1     ADEKA 1413/CN
E10           1     ADEKA 2014FG/CN
E11           1     ADEKA 25R1/CN
E12           1     ADEKA 25R2/CN

=> s e3
L2            1 ADEFOVIR/CN

=> d l2

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   106941-25-7  REGISTRY
ED   Entered STN:  07 Mar 1987
CN   Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]- (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   9-(2-Phosphonylmethoxyethyl)adenine
CN   9-[2-(Phosphonomethoxy)ethyl]adenine
CN   Adefovir
CN   GS 0393
CN   PMEA
FS   3D CONCORD
MF   C8 H12 N5 O4 P
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS,
       BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
       CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA,
       MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
       USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   WHO
```



Me v. H adefovir

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

493 REFERENCES IN FILE CA (1907 TO DATE)
24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
493 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e cyclic cidofovir/cn
E1            1     CYCLIC CARBOXYETHYL-AICAR-3',5'-MP/CN
E2            1     CYCLIC CHLOROETHYLENE CARBONATE/CN
E3            0 --> CYCLIC CIDOFOVIR/CN
E4            1     CYCLIC CMP/CN
E5            1     CYCLIC CMP PHOSPHODIESTERASE/CN
E6            1     CYCLIC CYTIDINE 2',3'-PHOSPHATE AMMONIUM SALT/CN
E7            1     CYCLIC CYTIDINE MONOPHOSPHATE/CN
E8            1     CYCLIC D-TRYPTOPHANYL-L-TRYPTOPHAN/CN
E9            1     CYCLIC DAMP/CN
E10           1     CYCLIC DEOXYADENOSINE 3',5'-MONOPHOSPHATE/CN
E11           1     CYCLIC DI-GMP BINDING PROTEIN (BURKHOLDERIA PSEUDOMALLEI STR
                    AIN K96243 GENE BCSB)/CN
E12           1     CYCLIC DI-GMP BINDING PROTEIN PRECURSOR (ESCHERICHIA COLI ST
                    RAIN CFT073 GENE YHJN)/CN
```

CDV

```
=> e tenofovir/cn
E1            1     TENOBLOCK/CN
E2            1     TENOCYCLIDINE/CN
E3            1 --> TENOFOVIR/CN
E4            1     TENOFOVIR DF/CN
E5            1     TENOFOVIR DIPHOSPHATE/CN
E6            1     TENOFOVIR DISOPROXIL/CN
E7            1     TENOFOVIR DISOPROXIL FUMARATE/CN
E8            1     TENOFOVIR TRIPHOSPHATE/CN
E9            1     TENOLIN/CN
E10           1     TENOLOL/CN
E11           1     TENOMODULIN (HUMAN GENE TEM)/CN
E12           1     TENOMODULIN (HUMAN)/CN

=> s e3
L3            1 TENOFOVIR/CN

=> d l3

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   147127-20-6  REGISTRY
ED   Entered STN:  22 Apr 1993
CN   Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, (R)-
OTHER NAMES:
CN   (R)-9-(2-Phosphonomethoxypropyl)adenine
CN   GS 1275
```

10/759,345

CN GS 1278
CN PMPA
CN **Tenofovir**
FS STEREOSEARCH
MF C9 H14 N5 O4 P
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



Tenofovir

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

327 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
333 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.19	23.67

STN INTERNATIONAL LOGOFF AT 12:46:09 ON 01 AUG 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available

NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:40:19 ON 01 AUG 2005

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 12:40:33 ON 01 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 29, 2005 (20050729/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 12:40:38 ON 01 AUG 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'REGISTRY' ENTERED AT 12:40:44 ON 01 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2
DICTIONARY FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *

****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> e cidofovir/cn
E1            1     CIDIROL/CN
E2            1     CIDOCETINE/CN
E3            1 --> CIDOFOVIR/CN
E4            1     CIDOFOVIR DIPHOSPHATE/CN
E5            1     CIDOFOVIR HYDRATE/CN
E6            1     CIDOMYCIN/CN
E7            1     CIDOPHYLLINE/CN
E8            1     CIDOTEN/CN
E9            1     CIDOVIR/CN
E10           1     CIDOXEPIN/CN
E11           1     CIDOXEPIN HYDROCHLORIDE/CN
E12           1     CIDR/CN

=> s e3
L1            1 CIDOFOVIR/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   113852-37-2  REGISTRY
ED   Entered STN:  16 Apr 1988
CN   Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-
     (hydroxymethyl)ethoxy]methyl]- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-
     (hydroxymethyl)ethoxy]methyl]-, (S)-
OTHER NAMES:
CN   (S)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine
CN   (S)-HPMPC
CN   1-(S)-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine
CN   1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
CN   Cidofovir
CN   Cidovir
CN   GS 0504
CN   HPMPC
CN   Vistide
FS   STEREOSEARCH
MF   C8 H14 N3 O6 P
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
       CEN, CHEMINFORMRX, CHEMLIST, CIN, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*,
       IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*,
       MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)

Absolute stereochemistry.
```